We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.01 | -0.04% | 27.77 | 28.12 | 27.72 | 27.83 | 42,862,116 | 23:59:59 |
By Colin Kellaher
Pfizer Inc. Friday said the European Medicines Agency accepted for review the drugmaker's marketing authorization application for its 20-valent pneumococcal conjugate vaccine candidate for adults ages 18 and older.
The New York company said the acceptance starts the formal review process by the agency's Committee for Medicinal Products for Human Use.
Pfizer's 20-valent vaccine candidate covers 13 serotypes already included in its Prevnar 13 vaccine, plus seven new serotypes. The company noted that the 20 serotypes are responsible for the majority of currently circulating pneumococcal disease worldwide.
The U.S. Food and Drug Administration in December granted priority review to Pfizer's application for the vaccine in adults, with a target action date in June.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2021 07:55 ET (12:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions